← Back to patent-cliff list
DBI-002
Tier C — Watch / tradeDBI-002
Dermbiont Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：Pityriasis versicolor, 脂溢性皮炎, Onychomycosis
Regional status
US
No progress
2023-11-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of DBI-002?
Approved indications include: Pityriasis versicolor, 脂溢性皮炎, Onychomycosis.
When does the DBI-002 patent expire?
No public expiry year is available for DBI-002 yet; this page updates once verified.
How do I get a quote for DBI-002 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06